CYP 1.82% 27.0¢ cynata therapeutics limited

IPO's and valuations, page-167

  1. 1,848 Posts.
    lightbulb Created with Sketch. 218
    "Doesn't matter which side of the fence the IP for iPSC production is on, it is covered by various patents and patent applications in process, licenced to Cynata - signed pre FujiFilm/CDI takeover back in 2014."

    It does matter. Post me offline if you want and I will show you why - or keep discussing online I don't mind.

    Please stop being defensive (I am only picking on you to get you to be clearer because you weren't being clear and consequently you were confusing people who actually want to learn).

    The real (as opposed to imaginary) synergies Celularity and CYP may find depends on the actual IP CYP holds and on the actual cells CYP can make available to Cellularity to work with.

    I think you referrred me to the prospectus (with its license agreement summary from WARF) - it separates IP into three schedules. Not all the IP CYP has is exclusive.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.